מן הרשת 21.12.202317:17 Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Urothelial Carcinoma A Systematic Review and Meta-Analysis - Beyond the Abstract Uro Today
מן הרשת 21.12.202317:16 Disease detection and adjuvant treatment decision-making for bladder cancer Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials Transl Oncol.
מן הרשת 21.12.202317:15 Mutations that Predict Exceptional Polymerase Inhibitor Sensitivity in Prostate Cancer Co-Occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer Uro Today
מן הרשת 21.12.202313:43 FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial cancer (la/mUC) FDA
מן הרשת 21.12.202313:41 FDA approves belzutifan for advanced renal cell carcinoma On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) FDA
מן הרשת 21.12.202313:40 IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC OncLive
מן הרשת 21.12.202313:39 Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC SUO 2023: Late Breaking Abstract: First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC Uro Today
מן הרשת 19.12.202315:47 האם חלף עידן הכימותרפיה בקו ראשון בסרטן שלפוחית שתן גרורתי? FDA Approves New First-Line Standard of Care in Bladder Cancer MedPage Today
מן הרשת 31.10.202313:19 Biochemical Recurrence in Prostate Cancer — Tilting the Scale The state of biochemical recurrence in prostate cancer is one in which rising serum prostate-specific antigen (PSA) levels point to the existence of disease that remains radiographically invisible on computed tomography and technetium-99m bone scans NEJM
מן הרשת 31.10.202313:18 Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown NEJM
מן הרשת 16.07.202311:30 Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab We evaluated the association of corticosteroids with survival outcomes during nivolumab treatment in patients with mccRCC JAMA Oncology
מן הרשת 12.07.202312:01 פריצת דרך בקו ראשון שלפוחית השתן גרורתי שילוב של Nivolumab כתרופה אימונית בודדת עם טיפול כימי מבוסס ציספלטין משפרת PFS ותוחלת חיים BMS
מן הרשת 02.04.202310:55 New Cancer Data Spark Outcry From Patient Advocates Newly released figures showing a rise in the number of men with advanced prostate cancer have laid bare long-simmering resentment among patient advocates who feel the nation's leading cancer group has largely ignored their concerns for years Medscape
מן הרשת 02.04.202310:54 COVID Can Mimic Prostate Cancer Symptoms To avoid the risk for a gross misdiagnosis after a radical spike in PSA, the informed urologist should ask the patient if he has had COVID-19 in the previous 6 months Medscape
מן הרשת 02.04.202310:53 Omit Digital Rectal Exam in Prostate Cancer Surveillance? Routine use of MRI during active surveillance of men with prostate cancer allows patients to skip digital rectal examinations and some biopsies, and this approach is best practice, according to an international panel of experts Medscape